Why the study?
Does the carcinostatic agent MIH inhibit monoamine oxidase in a guinea pig model?
Does the carcinostatic agent MIH inhibit monoamine oxidase in a guinea pig model?
Answers are grounded in this paper and cite their sources.
The carcinostatic agent MIH exhibits significant monoamine oxidase inhibition, warning clinicians of potential MAOI-associated side effects when treating malignancies.
SummaryN-isopropyl-α-(2-methylhydrazino)-p-toluamide (MIH), a methylhydrazine derivative, is a member of a new class of carcinostatic agents with significant therapeutic effect in the treatment of Hodgkin's disease. It was found to inhibit guinea pig liver monoamine oxidase to a significant degree with a prolonged effect after a single dose. The compound was not as potent as a known MAO inhibitor, pheniprazine (JB 516). The CNS effects of a tryptophan load following a single dose of MIH were minimal; however, following chronic treatment with MIH, such a tryptophan load produced lethal convulsions indicating significant inhibition of brain MAO. The clinical implications are discussed. Physicians using this compound in the treatment of malignancies should beware of unwanted side effects associated with monoamine oxidase inhibitors.
No takes yet. Share an insight, caveat, or question.
Vita et al. (1965) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: